NCT07693543Not yet recruitingPhase 2
Nicotinamide Riboside Supplementation in Chronic Kidney Disease
Pilot Randomized Crossover Trial of Nicotinamide Riboside in Chronic Kidney Disease (NR-CKD Trial)
Source: ClinicalTrials.gov · Last updated 15 Jul 2026
Brief summary (registry, in English)
This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism. The main goal of this study is to see whether it is feasible for people with chronic kidney disease to take NR daily, complete study visits, and follow the study procedures. The study will also explore whether NR chloride affects markers of mitochondrial health, small blood vessel function, and physical function. Participants will be randomly assigned to one of two treatment orders. One group will take NR first and placebo second. The other group will take placebo first and NR second. Placebo looks like NR but does not contain active NR. Each treatment period lasts 12 weeks, with an approximately 2-week washout period between treatments. Neither participants nor the study team will know which treatment participants are taking during each period. Study visits will include blood and urine collection, physical function testing, and noninvasive tests of small blood vessel function. The study will enroll up to 36 adults with moderate chronic kidney disease at the University of California, San Diego.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 29 Jun 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- University of California, San Diego
- Diseases
- Chronic kidney disease
- NCT number
- NCT07693543
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 1 Oct 2026 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of immunosuppressive medications, including steroids or calcineurin inhibitors.
- Hospitalization for myocardial infarction, unstable angina, cerebrovascular accident, or unstable cardiac chest pain within the prior 3 months.
Other illness
- End-stage liver disease with cirrhosis.
- HIV.
- Malignancy requiring active treatment or currently under surveillance at the discretion of the investigator.
Other
- Pregnancy.
- Expectation to start dialysis within 6 months.
- Unable to walk unassisted from room to room.
- Institutionalization or inability to consent.
- Oxygen-dependent COPD.
- Baseline systolic blood pressure \>170 mmHg or diastolic blood pressure \>100 mmHg.
- Current participation in another interventional trial.
Who the study is looking for
- Moderate chronic kidney disease not treated with dialysis, defined as eGFR 30-59 mL/min/1.73 m2 using the CKD-EPI equation.
- Urine albumin-to-creatinine ratio (uACR) \<300 mg/g.
- Able to provide informed consent.
- Able to walk unassisted from room to room, with usual assistive device allowed if approved by study safety assessment.
- Willing and able to comply with study procedures, visits, and study product administration.
Age in the registry: 30 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Altman Clinical and Translation Research Institute Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.